Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Translational Research Office (TRO) manage a number of devolved funding streams targeting early stage proof-of-concept projects and have extensive knowledge of the UK translational funding landscape. We can help source the most appropriate funding scheme for projects and ensure that the most compelling cases for support are generated. Securing funding enables projects to progress along the translational path, de-risking future investment.

Illustration of financial concepts, including graphs, calculator and percentages

KEY ACTIVITIES

The TRO administrate translational proof-of-concept funding through the Medical and Life Sciences Translation Fund (MLSTF). The fund is open to all University of Oxford researchers and provides consolidated internal proof of concept funding for translational medical and life sciences projects.

 

The TRO is excited to announce the return of the Diagnostics in Tropical and Infectious Diseases funding call, building on from the successful piloting last year. The availability of funds, recently awarded by Wellcome, supports early-stage translational research activity within the Oxford community.

The TRO also identify the most appropriate external grant funding source for a project. A few of the translational research funding schemes available to researchers are:

Award

Application deadline(s)

Award volume and duration

Comments

 

Gap fund for early-stage development of new healthcare interventions

UKRI logo

12th November 2025 4:00pm UK time

£50,000 - £300,000

You can apply for academically led translational projects that aim to undertake a focused package of work that will bridge the gap between the inception of a new idea and substantive funding through schemes such as the MRC Developmental Pathway Funding Scheme (DPFS) to:

  • help prevent disease
  • help improve speed and accuracy of diagnosis of disease
  • develop new treatments for disease
  • help to improve outcome monitoring of patients receiving treatment
  • help to improve the management of diseases and conditions

All human diseases and medical interventions are eligible for support, both in the context of UK healthcare and addressing global health issues.

Equalize Startups

Equalize Startups logo

14th November 2025

 

Equalize Startups is a nonprofit launchpad dedicated to fueling the success of women founders in academia.

The six-month programme offers expert training, personalised mentoring, in person networking, and a pitch competition – all designed to help women academic inventors successfully navigate the startup ecosystem.

Equalizers must hold an academic appointment—tenured, tenure track, or research—or a post-doc or graduate student position at an academic research institution and have a pending or issued patent or copyright.

MRC Developmental Pathway Funding Scheme: Stage One

UKRI logo

19th November 2025 4:00pm

There is no limit on the amount of funding you can apply for, but it should be appropriate to the project. 

There is no limit to the duration of your project. You should justify the timescale of the project in the context of the proposed work.

Apply for funding to develop and test novel therapeutics, medical devices, diagnostics and other interventions.

You can apply for academically-led translational projects that aim to either:

  • improve prevention, diagnosis, prognosis or treatment of significant health needs
  • develop research tools that increase the efficiency of developing interventions

Biology to Prevention Award

CRUK logo

4th December 2025

Flexible, from around £100k up to £600k for up to 5 years

Biology to Prevention Awards support translational research that advances our understanding of the biological mechanisms underlying cancer aetiology, genesis, and risk, with the goal of developing precision prevention interventions. The award will fund high quality, hypothesis-driven research with clear objectives and clear relevance to cancer prevention as outlined in our prevention research strategy. 

Sanofi iDEA-TECH Awards Europe 2025-2026

Sanofi logo

12th December

120 000€ in funding to support 1-year projects

This program seeks to explore emerging science and technologies that can be applied across the therapeutic pipeline, with focus areas including real-world evidence, novel modalities, advanced imaging, multi-omics, disease modeling, process innovation, and safety assessment.

For more information on iDEA-TECH Awards in general: Sanofi iDEA-iTECH Awards - Europe.

MRC Developmental Pathway Funding Scheme: Stage Two

UKRI logo

 

 

Only if invited

There is no limit on the amount of funding you can apply for, but it should be appropriate to the project. 

There is no limit to the duration of your project. You should justify the timescale of the project in the context of the proposed work.

Apply for funding to develop and test novel therapeutics, medical devices, diagnostics and other interventions.

You can apply for academically-led translational projects that aim to either:

  • improve prevention, diagnosis, prognosis or treatment of significant health needs
  • develop research tools that increase the efficiency of developing interventions

Cancer Research Horizons Seed Fund

Logo for Cancer Research Horizon

Rolling deadline

£50k to £100-£500k, with ability to invest up to £1m on occasion.

Early-stage validation, pre-seed, seed, and follow-on capital available.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Data Innovation Awards

Logo for Cancer Research Horizon

Rolling deadline

<£75k, <12 months

Funding to support cleaning, annotation, curation, linking or storage of CRUK-funded data that has significant commercial potential.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Entrepreneurial Programme

Logo for Cancer Research Horizon

Various (please check website)

£10k to £70k

Training opportunities to learn how to pitch your idea, build a business and attract investment.  Early market discovery, accelerator, and startup funding available.

Contact: Gillian.Shuttleworth@cancer.org.uk

Cancer Research Horizons Project Development Fund

Logo for Cancer Research Horizon

Rolling deadline

<£50K (£50K + applications considered if strong rationale),<12 months

To bridge a gap to get your project to the next stage.

Proposal should have a clearly defined endpoint that is achievable in the short to medium term). CRUK-funding is a prerequisite and proposals must be consistent with Cancer Research Horizon's vision and purpose

Contact: Gillian.Shuttleworth@cancer.org.uk

Therapeutic Catalyst - Cancer Research UK

Cancer Research UK - Wikipedia

Open until awarded.

£250k

18 months

Up to £250k for projects lasting up to 18 months. Drug discovery proposals, including, but not limited to:

- Deconvolution and validation of novel targets and pathways with clear therapeutic potential

- Novel therapeutic approaches to validated targets

- Development of platforms, assays and screens to identify novel cancer therapeutics or targets.

The TRO supports developing robust project plans and compelling applications for funding. Our Translational Research Managers can support grant writing activities, provide project management support and advise on long-term translational research strategies.

The TRO works closely with Oxford University Innovation (OUI), the Medical Sciences Business Partnerships Office (BPO) and University of Oxford's Research Services (RS) to ensure appropriate expertise and advice is sought at key stages in project development.